# SELLAS Life Sciences Group Inc. (SLS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.86, market value $2.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). SELLAS Life Sciences Group Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 20.3×**. The shares trade at 20.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -37.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -47.7%**. Each dollar of assets produces -47.7% of profit.

## Growth
- **EPS growth (1 yr): 50.0%**. Earnings per share rose 50.0%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Current ratio: 10.72** (quick 10.72). Current assets cover the next year's liabilities 10.72 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. SELLAS Life Sciences Group Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 678.7%** (YTD 267.6%, 3-mo 68.4%). The shares are up 678.7% over twelve months including dividends.
- **From 52-week high: -12.7%** (897.1% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 1.99** (volatility 105%). Beta of 1.99 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SLS · Page: https://foliofundamentals.com/stocks/sls

Not investment advice.